Six questions and answers by MetrioPharm CEO Dr. Wolfgang Brysch on the compound MP1032 in COVID-19
Is MetrioPharm developing a compound for the treatment of COVID-19?
Wolfgang Brysch: We are developing our lead compound MP1032 for the treatment of chronic inflammatory diseases, with the molecule targeting oxidative stress. Oxidative stress also plays a central role in COVID-19 disease...
2019 was the year of spectacular news, generated from the field of aging research. Supposedly, scientists had succeeded in slowing down the aging process, stopping it, even reversing it. As if life was an hourglass and we had learned how to stop time from running out by popping a pill, or even how to reverse the life flow.
How safe is MP1032? And why is that so important to us?
Our Phase II clinical trial in psoriasis is almost completed. And we are especially interested in one question: Has the good safety profile from our previous studies been confirmed? Nobody wants avoidable side effects. But does it really make sense that we place so much emphasis on a good safety profile in the development of MP1032?
The connection between chronic inflammation and diseases of aging
Is there a
problem with increasing life expectancy? If you look at the graph of average
life years alone, the development over the last fifty years looks very
positive. This graph shows a steady upward trend, especially in Western
countries. People are getting older continuously.
There is, however, a second graph that has risen much slower: that of healthy life expectancy...